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Abstract: Globally, we are facing a worrying increase in type 1 diabetes mellitus (T1DM) incidence,
with onset at younger age shedding light on the need to better understand the mechanisms of disease
and step-up prevention. Given its implication in immune system development and regulation
of metabolism, there is no surprise that the gut microbiota is a possible culprit behind T1DM
pathogenesis. Additionally, microbiota manipulation by probiotics, prebiotics, dietary factors and
microbiota transplantation can all modulate early host–microbiota interactions by enabling beneficial
microbes with protective potential for individuals with T1DM or at high risk of developing T1DM. In
this review, we discuss the challenges and perspectives of translating microbiome data into clinical
practice. Nevertheless, this progress will only be possible if we focus our interest on developing
numerous longitudinal, multicenter, interventional and double-blind randomized clinical trials to
confirm their efficacy and safety of these therapeutic approaches.
Keywords: microbiota; type 1 diabetes; microbiome; diet; dysbiosis
1. Introduction
The human gastrointestinal tract (GIT) is home to almost 1000 different bacterial
species, as well as viruses and fungi. Among these, the most abundant bacterial phyla are
represented by Bacteroidetes, Firmicutes, Proteobacteria and Actinobacteria [1]. The microbiota
population is stabilized by the age of three and is modulated by maternal diet composition,
delivery mode, early nutrition (breast-milk versus formula feeding), intake of antibiotics
and environmental factors (particularly hygiene level) [2].
The microbiota thrives in the nutrient-rich GIT and, in turn, provides several benefits
for the host including digestion of dietary substrates, vitamin synthesis, modulation of the
immune system, and protection against enteric pathogens via competition for nutrients and
production of bacteriocins/other antimicrobial metabolites (i.e., hydrogen peroxide, lactic
acid, etc.). A health-promoting microbiota is characterized by a certain level of microbial
abundance and diversity that are not highly affected by transient perturbations caused by
infections and antibiotic treatment and is also enriched in genes involved in fermentation
and biosynthesis of short-chain fatty acids (SCFAs) [3].
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Numerous studies from the last decade have shed light on the fact that microbiota is
not just a collection of microorganisms that inhabit us, but a pivotal player for our health.
Imbalances in the microbiota (also known as dysbiosis) are triggered by a multitude of
factors including diet, pathological conditions (i.e., inflammatory bowel disease, cancer
etc.), antibiotic intake, infections, stress and other environmental factors. In contrast,
microbiota is an essential contributor to the development and progression of many diseases
and therefore microbiota modulation holds promise as a potential therapeutic strategy.
Globally, we are facing a worrying increase in type 1 diabetes mellitus (T1DM) incidence,
with disease onset at younger age [4]. Research efforts have been made in the last few years
and we have a general picture of the microbiome patterns linked to T1DM. Even though
these studies reveal that taxonomic changes in the microbiota of T1DM patients are quite
modest, a functional depletion in short chain fatty acids (SCFAs) production is commonly
encountered across various studies and population groups [5].
Nevertheless, there is a paucity in studies correlating microbiota data with other host
factors (i.e., metabolome, proteome, epigenetic markers, diet, etc.) as well as translating
microbial diversity information into dietary/therapeutic intervention strategies. Within
this review, we briefly highlight the microbiome features identified in T1DM patients
together with the current intervention strategies targeting the gut microbiota and, last but
not least, we discuss the challenges and perspectives of translating microbiome data into
clinical practice.
2. Type 1 Diabetes Mellitus and the Microbiota—A Chicken and Egg Situation?
Diabetes mellitus (DM) is a heterogeneous disease, out of which type 1 DM (T1DM) is
characterized by absolute lack of insulin that mainly results from autoimmune destruction
of pancreatic beta cell mass (type 1A) [6]. In several cases only, in spite of a strong
inheritance (type 1B), the cause of beta cell destruction is unknown [6]. As a population-
wide screening for beta cell targeting autoimmunity is not yet established, the epidemiology
of T1DM is based on either plasma glucose or HbA1c criteria, and classic symptoms of
hyperglycemia [6]. The incidence rates of T1DM are increasing worldwide by 1.8–5% per
year [7,8], and differ extensively upon geography and different ethnic populations [9], with
highest occurrence in countries from Northern Europe and Canada [10]. The explanation
for this variation remains unclear, although it may be related to specific risk factors, such
as genetic susceptibility (i.e., population with certain types of HLA and multiple non-HLA
loci) and environmental triggers (i.e., hygiene and infections) [11].
As T1DM does not occur in many subjects harboring genetic susceptibility clearly
demonstrates the importance of other determinants responsible for actual T1DM increase
in incidence [12]. The environmental exposure confers an additional risk for islet targeting
autoimmunity [10,11]. Numerous environmental triggers (i.e., viral infections, gestational
infections, childhood immunization, diet, especially the timing of first introduction of food)
are thought to contribute to pancreatic beta cell destruction, but the mechanisms involved
remain largely unknown.
However, recent data [13] support the essential contribution of exogenous triggers
to rapid increase in T1DM incidence. In this scenario, the role of human microbiota in
the development of (auto)immune diseases and T1DM has recently gain higher interest,
as its close relations with the immune system [14] and chronic inflammation [15], and
its profound and permanent changes with environmental factors [16]. Consecutively,
the dysbiosis associated with (gut) microbiota modifications raises the need to better
understand its significance as contemporary or causal phenomena in T1DM [17]. Evidence
of a possible link between microbiota and T1DM has emerged from several animal studies.
For instance, administration of single antibiotics (i.e., vancomycin) or cocktails of antibiotics
triggered microbiota changes in non-obese diabetic (NOD) mice leading to accelerated or
delayed disease progression [18–22].
The causative link microbiota-T1DM was proven in murine models. It was shown that
T1DM development is in close relation with the host innate immunity. Hence, interaction of
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the commensal biota with the innate immune system impacted the onset and progression of
T1DM. Toll-like receptors (TLRs), are crucial players in the innate immunity and intestinal
homeostasis. Importantly, microorganisms can affect autoimmunity of T1D via signaling
through TLR family receptors [23–25]. Interestingly, NOD mice deficient in MyD88, an
adaptor molecule for TLR signaling, did not develop T1DM under conventional SPF
(specific pathogen free) conditions but this protection was abolished under germ free
conditions [26]. Moreover, T1DM incidence was reduced when MyD88 deficient mice
were exposed to a predefined microbiota mixture, further highlighting the close connection
between the microbiome and host immunity [26].
Another way by which bacteria can impact T1DM pathogenesis is through production
of short chain fatty acids (SCFAs) such as butyrate, propionate and acetate. Several research
reports linked abundance of butyrate-producing species with T1DM risk [27–30]. Studies
show that butyrate may exert epigenetic effects with a paramount role in T1DM such as
histone acetylation in the promoter of the Foxp3 locus responsible for the differentiation of
regulatory T cells or inhibition of histone deacetylases in macrophages [31–33]. However,
current data does not elucidate whether SCFAs induce tolerance by modulating either host
microbiome or inflammatory response [34].
Opposite to most previous reports [35,36], studies from recent years have shown that
in the case of T1DM, microbiota changes occur prior to systemic signs of islet autoim-
munity [37,38]. The reason for this shift may resides in that the microbiota modifications
were mostly detected only by gene analysis of 16S rRNA, which may not identify specific
structural and/or functional characteristics potentially involved in disease progression.
Later studies addressed this issue both by a specific design allowing to control for all
known factors interfering for T1DM susceptibility and microbiome characteristics [38], and
by longitudinal metagenomic sequencing of stool samples [37]. Regardless of geographical
location, the T1DM environmental niche was shown to harbor a proinflammatory envi-
ronment colonized by higher level of Bacteroidetes and low abundance of Firmicutes [39].
It has been suggested that the reduction in Firmicutes may be detrimental for the host
because this phylum reunites many producers of the SCFA butyrate, known to be involved
in intestinal homeostasis. Moreover, the Bacteroidetes phylum is comprised, among others,
of Bacteroides and Prevotella strains [39]. Many studies have shown that T1DM is dominated
by Bacteroides, a taxa correlated with intestinal inflammation whereas Prevotella, believed to
be protective, is reduced [40].
Regardless of the great variability found in T1DM associated microbiota, several stud-
ies consistently reported that Bacteroides was linked to T1DM development [27,28,41–44].
Indeed, species belonging to this genus can ferment glucose and lactate to propionate,
acetate, and succinate [45] while not being able to generate butyrate [46]. Butyrate is a
crucial metabolite for intestinal homeostasis that stimulates mucin synthesis [47] and can
also decrease gut permeability by enabling the assembly of tight junctions (TJ) [48]. In ad-
dition lactate producing bacteria, including some probiotic strains (Lactobacillus rhamnosus
and L. reuteri [49], L. johnsonii N6.2 [50], L. plantarum [51], Bifidobacterium lactis [52] may
synthetise butyrate [53] and, thus, strengthen the intestinal barrier function.
All these findings paint the picture for microbiota involvement in T1DM pathogenesis
but, nevertheless, conclusions from animal studies need to be taken with caution [54].
Some studies reported that alterations in microbiome composition were evident prior to
T1DM development [27,28,36,55]. However, these were prospective studies that presented
a timeframe of disease progression linked to microbial dysbiosis, and to address the issue
of a causal contribution of the microbiota in this ailment, intervention studies are needed.
Knowledge regarding the involvement of probiotics in this equation is still scarce.
Nevertheless, early administration of probiotics during the first four weeks of life di-
minished the risk of beta cell autoimmunity in subjects genetically susceptible to T1DM
when compared to those that received no probiotics [56]. Administration of the prebi-
otic oligofructose-enriched inulin in a single-center, randomized, double-blind, placebo-
controlled pilot study in children with T1DM was shown to improve beta cell function and
Int. J. Mol. Sci. 2021, 22, 2763 4 of 17
intestinal permeability. Nevertheless, prebiotic administration did not improve glycaemic
control likely due to the small sample size analyzed [57]. Even though interventional hu-
man studies suggest a microbial involvement in T1DM, a causal relationship still cannot be
inferred due to the lack of large-scale prospective studies that clearly demonstrate that mi-
crobiome changes alter T1DM risk. Future randomized controlled studies in large cohorts
are still necessary. For instance, there are no human studies to address the link between
antibiotic intake—microbiota changes—T1DM or between FMT-microbiota-T1DM.
3. Translational Applications—Moving from Fundamental Research to Improved
Diagnosis and Therapeutic Strategies in T1DM
As our knowledge in the microbiome field expands, it is becoming more evident that
reshaping the gut microbiota through various strategies (i.e., diet, probiotics, prebiotics,
fecal transplant) holds promise in T1DM therapy in terms of halting disease progression
and even prevention (Figure 1). Personalized changes in the host microbiota, customized in
accordance to the host genetic background may be a powerful new approach in prevention
and treatment.
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Figure 1. Gut microbiota and T1DM. T1DM patients harbor a microbiota with reduced diversity enriched in Bacteroides
species (B. dorei, B. ovatus, B. logum). The gut environment in T1DM is characterized by increased gut permeability, disrupted
mucus barrier, inflammation and low production of SCFAs (particularly butyrate).
3.1. Diet
It is well established that microbiota composition is highly dependent on host diet [58].
In subjects with autoimmune diseases, microbiota suffers significant differences compared
with healthy persons [30,59,60]. The link between diet inductors of gut dysbiosis (i.e.,
fat from bovine milk, protein from fresh milk or gluten) and subsequent development of
T1DM has been suggested in several human studies [61–63]. The impact of dietary style on
intestinal microbiota and the occurrence of T1DM is furthermore demonstrated by studies
involving second generation of immigrants coming to Sweden [64]. Post-immigration
occurrence of metabolic diseases in relation with diet modifications were also reported in
migrants coming to U.S [65].
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Experiments on mice have shown that a high-protein diet leads to an increased level
of IGF-1 (insulin-like growth factor 1) which is correlated with a high risk of developing
diabetes. Studies on mice fed with solid animal fats have revealed a greater abundance
of species of the genus Bacteroides and Bilophila, while in mice fed with fish oil dominated
the Bifidobacterium, Adlercreutzia, Lactobacillus, Streptococcus genera and A. muciniphila.
The mice fed with lard developed inflammation in the white adipose tissue, low insulin
sensitivity, TLR (Toll-like receptor) activation, as opposed to those fed with fish oil [66]. The
artificial sweeteners such as saccharin, sucralose, and aspartame have been proposed as an
alternative to natural sugar and promoted as healthy and without calories, although they
are quite controversial and the opinions and expert opinion is divided. The consumption of
artificial sweeteners has many consequences such as structural and functional alterations
of the intestinal microbiome, causes glucose intolerance and determines a predisposition to
diabetes [67].
Data from human and animal studies suggest that early exposure to foreign food
antigens such as bovine insulin and gluten may be involved in β-cell immunity [68,69].
Therefore, it is not surprising that diet is also an important contributor to T1DM onset
and progression. As previously mentioned, a leaky gut barrier is commonly encountered
in T1DM [41]. Gluten was shown to harbor various effects in the body, starting from the
intestine where it may alter microbiota composition triggering enteropathy and intestinal
permeability [70]. Moreover, these effects can be modulated by a gluten free diet [71]. As
revealed by animal studies, a gluten free diet may dampen the innate and adaptive immune
system proving to be beneficial for the host [71]. In human T1DM, several intervention
strategies have been proposed including gluten exclusion during pregnancy combined
with early gluten introduction, mucosal tolerance induction to gluten as well as gluten free
diets [71]. Gluten-based diets were linked to gut permeability alterations via microbiome
modulation [72]. For example, taxa associated to a gluten free diet (i.e., Akkermansia sp.)
were reported to impact gut permeability by regulating tight junction proteins and to be
protective in case of T1DM [73].
Both animal and human studies reveal the fact that early exposure to gluten (<3 months
in humans) raises the risk to develop islet autoimmunity [74,75]. In patients with genetic
predisposition, who are positive for HLA DQ2/DQ8, gluten activates the specific T lympho-
cytes, leading to mucosal destruction, hyperplasia of intestinal crypts, as well as subtotal
or total vilositary atrophy [76].
Though, in both celiac disease and T1DM, the effects of gluten free diet are still contro-
versial. Hence, it was reported that in children with established T1DM and concomitant
biopsy diagnosis of coeliac disease over a 10-year period, gluten-free diet significantly
improved both weight, height, and BMI adjusted for age, and improved diabetes control
by reducing daily insulin doses [77]. In NOD mice, gluten free diet prevents diabetes
by reducing the number of caecal bacteria [78]. However, other reports did not find a
significant effect [79,80].
Cow’s milk is another dietary factor believed to be involved in T1DM but this aspect
is a subject of controversy. While some studies highlight that bovine milk proteins may
be a culprit in mounting a humoral immune response leading to disease onset [81], other
studies found no differences [82] or even implied that cow’s milk formula has a beneficial
effect against T1DM [83]. Moreover, cow’s milk formula containing bovine insulin was
shown to trigger an autoimmune response to insulin. In addition, a subsequent study
(Finnish Dietary Intervention Trial for the Prevention of T1DM) reported that milk formula
without bovine insulin reduced the risk of β-cells autoimmunity [84].
Breast milk induces dose dependent changes in the infant microbiota that correlate
with specific bacteria (i.e., Bifidobacterium and Lactobacillus) transferred from maternal
microbiota [85,86]. As for gluten, murine studies suggested that for breast milk the timing
of introduction is essential for an efficient microbiome regulation of the infant’s immune
system [87]. Hence, it has been shown that infants that were breastfed only during first
6 months of life have developed a distinct pattern of microbiota [1]. Moreover, it is
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suggested that breast milk protects against T1DM occurrence in children with genetic
predisposition [88].
Recent data [89] have shown that the occurrence of islet autoimmunity and the pro-
gression towards T1DM in genetically predisposed children was not influenced either
by the age of solid food introduction or by the duration of breastfeeding. These results
support previous observation showing that breastfeeding alone may interfere with T1DM
occurrence [90,91]. Nevertheless, how and to what extent dietary factors influence T1DM
pathophysiology is an important aspect that awaits future research.
Permanent dietary changes can trigger the enrichment of beneficial taxa shaping the
intestinal homeostasis, but we have to highlight the paramount importance of the patient
ability to adhere to certain diets. Moreover, one major challenge in this field is to decipher
the high variability in individual responses to food intake. People differ greatly in their
responses to diet intervention due to a wide array of factors some of which are non-food-
specific factors (sleep, meal timing and activity). Hence, dietary interventions hold promise
in improving host health but their implementation should be carefully optimized using
rigorous prediction algorithms.
3.2. Probiotics—The Promises and the Unmet Needs
Probiotics are microorganisms (bacteria, fungi) commonly regarded as safe that, when
administered to a subject, promote a wide range of beneficial effects including modulation
of gut microbiota and immunomodulation.
Most of the progress in understanding and developing microbiome therapeutics
has emerged from rodent models. However, rodents and humans harbor fundamentally
different microbiomes, so making the transition from one to another needs to be performed
with caution. Several probiotics are currently being used in clinical trials to correct the
dysbiosis linked toT1DM [92].
Besides the well-known lactobacilli, promising probiotics that are potent SCFA producers
(especially butyrate) such as Roseburia intestinalis, Eubacterium halli and Faecalibacterium spp.
can be employed in clinical trials [93]. For instance, probiotics such as B. lactis Bb12L
and L. rhamnosus GG are currently being investigated for their protective role in a clinical
study in children with newly diagnosed T1DM [72]. Notably, probiotic administration
(lactobacilli and bifidobacterial species) early in life was significantly correlated with a
reduced autoimmunity risk in subjects harboring an HLA-DR3/4 genotype [56]. Cur-
rently, several ongoing clinical studies are investigating the role of probiotics such as
L. johnsonii, L. plantarum, L. salivarius AP-32, VSL#3, and B. animalis subsp. lactis CP-9 in
T1DM management (NCT03880760, NCT03423589, NCT03423589, NCT04141761, NCT03961854,
NCT04335656). Most of these clinical studies are in the recruitment phase but, once com-
pleted, they may provide a better picture regarding the impact of probiotic supplementation
on metabolic profile (blood glucose, HbA1c), systemic inflammation, host transcriptome,
gut barrier function, and microbiome profile.
Even though a series of recent papers have addressed the various microbiota patterns
linked to diabetes, still there is research needed to assess the impact of microbiota manip-
ulation on development of diabetes complications [5,17,40,54,72,94–97]. Specifically, the
complications triggered by diabetes can be either microvascular (nephropathy, retinopathy,
and neuropathy) or macrovascular (i.e., cardiovascular disease, peripheral vascular disease,
cerebrovascular accidents). In the last few years, several research groups have investigated
this aspect particularly in the case of diabetic nephropathy. Indeed, gut microbiota is
impaired in chronic kidney disease likely due to elevated uremia which halts intestinal
barrier function triggering intestinal inflammation which in turn may disturb the renal
parameters. Therefore, manipulation of gut microbiota may positively modulate the renal
profiles in these patients. The results emerging from studies of probiotic use in diabetes
complications are summarized in Table 1. Most of the microorganisms used in these studies
belonged to the Lactobacillus and Bifidobacterium genra whereas the dosage ranged from
2 × 107 to 6 × 1010 CFU/g. The form of the probiotics varied across the studies (capsules,
Int. J. Mol. Sci. 2021, 22, 2763 7 of 17
soy milk, sachets, kefir and honey). Most studies demonstrated the benefits of probiotic
supplementation on diminishing inflammation, oxidative stress and on the amelioration of
renal function biomarkers in patients with diabetic nephropathy.
Table 1. Studies of probiotic use in diabetes complications.
Study Group Details Treatment Outcome Reference
Diabetic nephropathy, 44
subjects probiotic (n = 22)
placebo (n = 22)
Soy milk containing L.
plantarum A7 adminsitered for
8 weeks
Significant impact on lipid
profile and glomerular
function
Abbasi et al., 2017
[98]
Diabetic nephropathy, 136
subjects probiotic (n = 68)
placebo (n = 68)
L.acidophilus, L. casei, L. lactis,
B. bifidum, B. infantis, B.
longum and with a daily dose
of 6 × 1010
12 weeks
The urea levels significantly
declined in the probiotic
group while her parameters of
renal profile as well as liver
function tests remained
unchanged
Firouzi et al., 2015
[99]
Diabetic nephropathy
60 subjects probiotic (n = 30)
placebo (n = 30)






reuteri strain ZT-Lre, and
L. fermentum
strain ZT-L3 (each 2 × 109)
12 weeks
Probiotics supplementation
for 12 weeks had beneficial
effects on glycemic control
and markers of





Mafi et al., 2018 [100]
Diabetic nephropathy,







12 weeks among diabetic HD
patients had beneficial effects
on the parameters of glucose
homeostasis and a few
biomarkers of inflammation
and oxidative stress
Soleimani et al., 2016 [101]
Diabetic nephropathy
60 subjects probiotic (n = 30)





lead to improved insulin
metabolism,
total-/HDLcholesterol,
plasma MDA levels, and
serum hs-CRP, and but did not
affect other metabolic profiles
Mazruei et al., 2019
[102]
Diabetic nephropathy, n = 48
48 subjects probiotic (n = 24)
placebo (n = 24)
200 mL/day probiotic (L.
plantarum A7 strain) soy milk
in the intervention group or
soy milk in the control group
8 weeks
DN participants in the
probiotic soy milk group had
higher levels of GSH
compared to those in the soy
milk group. Significantly
increased levels of glutathione
reductase and glutathione
peroxidase were reported for
the probiotic group







pressure in diabetic mice
Home, 2020
[104]
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Table 1. Cont.
Study Group Details Treatment Outcome Reference
Diabetes complicated by
coronary heart disease robiotic
supplements (n = 30) or
placebo (n = 30) for 12 weeks.
Oral administration of
2.5 × 109 CFU/g probiotic
containing B. bifidum, B. lactis,
L. acidophilus, L. brevis, L. casei,
L. salivarius, L. lactis and L.











compared to the placebo
group








apoptotic cell death in kidney,
improved diabetes-induced
collagen deposits in the
glomerular tuft and the
tubular epithelia in diabetic
mice. LP-A administration
also significantly improved
retinal gliosis, neuronal cell
death inflammation, and loss
of retinal vascular capillaries.
Li et al., 2018
[106]
Even though there is a high amount of research being done in the field of probiotics and
their positive effects on various ailments, there are still some challenges left. Importantly,
a probiotic strain needs to establish itself within the intestinal niche in order to elicit its
host beneficial effects. However, to do this, the probiotic strain may have to outcompete
the indigenous microbiota while being resistant to the host antimicrobial peptides. Since
we know that the host microbiota varies from individual to individual, we can say that
probiotic outcomes are individualized and, to some extent, unpredictable. Nevertheless,
some studies advocate that establishment of a probiotic within the gut microbiota is not
mandatory to elicit a beneficial effect. Therefore, while probiotics may be transient, they
may modulate the microbiome via the production of beneficial metabolites including
SCFAs.
Moreover, studies and clinical trials employing probiotics for treatment of T1DM (or
any other disease for that matter) need to provide information regarding patient details
such as age, gender, geographical location, comorbidities, medication taken, and nutrition
as well as the impact of probiotics on the host metabolome (particularly SCFAs, bile acids)
and immune system. Only such randomized, placebo-controlled studies may help us
decipher the gut-microbiome interplay and may guide us to identify which patients may
benefit from a certain probiotic or not.
3.3. Prebiotics—Potential Adjuvants in Glycemic Control
Prebiotics, defined as non-digestible food ingredients that modulate the microbiota by
serving as nutritional substrates for the growth and multiplication of probiotics, also hold
therapeutic potential. Inulin, human milk oligosaccharides, and lactulose are prebiotics that
boost the growth of various probiotic strains including bifidobacteria. Current management
of T1DM is based on multiple daily subcutaneous insulin injections or infusion and frequent
glycaemic monitorisation. Unfortunately, it is still challenging to reach optimal glycemic
control in these patients. Hence, in this scenario, adjunctive oral supplements in the
shape of prebiotics may help improve glycemic control. Within this line of thought, a
recent study by Ho et al. used oligofructose-enriched inulin in a randomized, placebo-
controlled trial performed in T1DM children. Treatment with oligofructose enriched inulin
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was shown to harbor beneficial effects in T1DM children by significantly increasing C-
peptide levels [57]. Moreover, a randomized, placebo-controlled trial recently showed that
prebiotics may positively impact glycaemic control through direct interventions on gut
microbiota by prebiotic administration and subsequent reducing of intestinal permeability,
thereby improving insulin sensitivity in young T1DM patients [107]. This study confirmed
in children with established T1DM previous observation on obese mice [108] that reduced
gut permeability involves an increased level of glucagon like peptide (GLP)-2.
Most of the studies addressing the impact of prebiotics on T1DM have been performed
on animal models and so far, not many clinical trials in humans exist. Notably, an acetylated
and butyrylated form of high amylose maize starch (HAMS-AB) that was shown to increase
SCFAs production and to be safe and effective in disease prevention in T1DM mouse models
is currently being used in a phase 3 clinical trial (NCT04114357) in children and adolescents
with recently diagnosed T1DM.
3.4. Faecal Microbiota Transplant—Solution or Potential Problem?
Host microbiota can be also modified by faecal microbiota transplant (FMT), which
involves the transfer of a ‘healthy’ microbiome into a recipient with dysbiosis with the
purpose to restore gut homeostasis. FMT is being used successfully in treating Clostridium
difficile infection, however its success in treating T1DM is largely unknown.
A recent study by de Groot et al. showed that autologous (i.e., from T1DM patients)
but not homologus (i.e., from healthy donors) FMT of colon-derived microbiota into
the intestine of patients with new onset T1DM lead to a prolonged residual beta cell
function. One possible explanation proposed by authors is that the autologous FMT is
more immunologically compatible with the host. The assumption is in line with the results
of the study showing that the preservation of beta cell function by autologous FMT is T cell
mediated, as CD4+ CXCR3+ and CD8+ CXCR3+ T cells were decreased differentially in
the responders.
In addition, the study identifies several taxa with therapeutic potential including
duodenal Prevotella spp. and S. oralis as well as faecal Desulfovibrio piger and Bacteroides
stercoris [109]. Both Prevotella spp. and S. oralis were negatively correlated with the most
important fasting plasma metabolite that changed upon FMT and with fasting C-peptide.
Bacteroides stercoris correlated positively with Desulfovibrio piger while the latter correlated
positively with another fasting plasma metabolite that changed upon FMT and with fasting
C-peptide. Moreover, Desulfovibrio piger was negatively correlated with CD4+ CXCR3+ and
CD8+ CXCR3+ T cells. These results suggest that taxa that changed upon FMT in subjects
with T1DM has beneficial effects either by preserving beta cell function or by suppressing
autoimmunity.
Nevertheless, one has to bear in mind the fact that while probiotic administration
transfers few microbial species to the recipient gut, FMT conveys a mix of various microor-
ganisms into the host, out of which some may possibly be hazardous for the recipient host.
Thus, in order to consider FMT as a potent therapeutic approach, composition of the faecal
microbiota for transplantation needs to be standardized prior to administration. Impor-
tantly, we still do not fully know the profile of the “perfect” donor and other problematic
factors including sustainability of the procedure and risk of infection need to be dealt with.
4. Omic Technologies—From Bench to Bedside
Multi omics approaches are an area of active investigation that may ultimately offer
opportunity for personalized treatment for many ailments. Importantly, most of the omics-
based studies on diabetes reported so far used mainly patient serum samples. Nevertheless,
it is important to also look into other types of samples (i.e., fecal samples) and to correlate
multi-omic approaches with the gut microbiota. Only in this way we can reconstitute the
flow of information from disease parameters to causes of disease (genetic or environmental),
functional consequences and treatment opportunities.
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Several research studies exist regarding multi omic analysis in case of diabetes but
most of them are focused on type 2 diabetes rather than T1DM [110]. Nevertheless,
transcriptomics analysis done by using microRNA (miRNA) microarray, followed by
qRT-PCR (quantitative Real Time PCR) validation showed some specific features linked
to T1DM. Thus, several miRNAs in peripheral blood mononuclear cells were reported
to be specific to T1DM: miR-103, let-7, miR-1260, miR-130a, miR-1274, miR-150 miR-720,
miR-193a-5p, miR-20b, miR-16-5p, miR-133a-3p, miR-142-5p, miR-409-5p, miR-501-3p,
miR-486-5p, miR-145-3p, miR-3150-3p and miR-1271-5p, with some of them being linked
to retinopathy and nephropathy [111–113].
Proteomic approaches have been used to elucidate the mechanisms of beta-cell dys-
function in diabetes. Thus, using proteomics diagnostic tools, six new T1DM autoantibodies
have been identified. More specifically, these autoantibodies are against receptor type
N2 (PTPRN2), protein tyrosine phosphatase, nucleoporin 50, mutL homolog 1 (MLH1),
peptidyl-prolyl cis-trans isomerase-like 2 (PPIL2), mitochondrial translational initiation
factor 3 (MTIF3) and pyroglutamylated RFamide peptide receptor (QRFPR) [114]. Besides
autoantibodies, serum adiposity proteins and immune molecules have been linked to
T1DM but their validity has yet to be studied through proteomics [115].
Even though metabolomics data may have a powerful impact on T1DM management,
current therapeutic approaches revolve around targeting high glucose levels and glyco-
sylated hemoglobin. It was reported that patients with diabetes (both type 1 and type 2)
harbored elevated levels of aromatic and branched-chain essential amino acids [116] which
are produced by members of the microbiota such as Escherichia coli [117]. Microbiota is
closely related to the metabolomic profile as it was recently shown for type 2 diabetes in
an elegant study by Nuli et al. (2019) [118]. Faecal metabolites such as protorifamycin I,
matricin, and epothilone A were negatively correlated with Actinobacteria. A similar testing
for the T1DM fecal metabolome awaits investigation [118].
Several reports have also linked T1DM autoimmune development with lipidomic
changes. Hence, changes in the metabolomic profiles of various classes of lipids, such as
triglycerides, plasma phospholipids, sphingolipids, glycerophospholipids, and cholesterol
esters, within the context of T1D have been reported [116,119–121].
Since the management of all types of diabetes comprises of dietary and lifestyle inter-
ventions, future work aiming to analyze how diet impacts metabolites and the microbiome
is essential.
The main advantage of using omics-based technologies is the fact they provide simul-
taneous detection of multiple molecules, helping to better understand and potentially treat
disease. Nevertheless, there is still a lot we need to understand in order to apply a person-
alized treatment approach in T1DM. It is imperative to further standardize and automate
these methods of analysis particularly in the case of metabolomics and proteomics in order
to make efficient and reproducible high-throughput analyses. Despite the great promise
of integrating big data multiomics into patient treatment, there are limitations as well as
ethical considerations currently halting its large scale implementation. Beside the logistic
concerns surrounding implementation of these technologies, these omic approaches are
very costly and, moreover, there is a general reluctance to change in health-care systems.
Unfortunately, though, there is also a fundamental lack of recognition by funding agencies
of the potential for omic-guided care to improve disease outcome.
We show here that several methods to tailor the host microbiota have good potential
in improving T1DM outcome. We believe that combining traditional sources of medical
information (i.e., laboratory workup, patient history) with data emerging from omic tech-
nologies (i.e., microbiome, metabolome) will enable patient stratification subsequently
aiding the clinician to choose the appropriate intervention strategies (diet, probiotics, fecal
transplant etc.). It is imperative to make the transition from the lab to the clinic so that we
can help deliver precision medicine to individual patients (Figure 2). Moreover, a patient
follow-up after the intervention is crucial.
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5. Conclusions
Clinical management of diabetes involves strategies targeting modifiable risk factors
that aim to reduce the development of specific complications. As lack of endogenous
insulin is the key element in pathogenesis of T1DM, exogenous insulin therapy is of
outmost importance. However, high variability occurs in response to classical therapeutic
interventions. Hence, clinical approaches in diabetes as well as in other ailments need to
switch from “one size fits all” to personalized medicine. A better understan ing of the
unique characteristics of each patient will explain the underlying causes f r differential
pharmacological responses and will improv treatment options. Knowl dge gained from
microbiome research is a promising step in T1DM field. Even though the studies presented
within this review offer a pictur regarding th microbiome thriving in the T1DM gut,
they generally targeted white populations with early-onset disease so there are still many
questions awaiting.
Nevertheless, by targeting the microbiota, we will be able to more precisely character-
ize and treat diabetes. Probiotics, prebiotics, dietary factors and microbiota transplantation
can all modulate early host–microbiota interactions by enabling beneficial microbes with
protective potential for individuals with T1DM or at high risk of developing T1DM. Never-
theless, this progress will only be possible if we focus our interest on developing numerous
longitudinal, multicenter, interventional and double-blind randomized clinical trials to
confirm their efficacy and safety of these therapeutic approaches.
Moreover, the advent of omics profiling technologies has a huge impact in identifying
unique biological signatures to allow personalized treatments in diabetes. Importantly,
omic technologies need be scaled up and made available to many individuals because
currently, many of these tools used in precision medicine are expensive and not accessible
in many parts of the world. Future research studies need to better characterize health-
associated taxa in correlation with their functional features (i.e., SCFAs production) and
their delivery to a recipient host. Importantly, the patient’s individual microbial profiles
should be characterized before employing personalized therapeutic approaches.
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